BUY CHAPTERS

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Code: ALLI-Auto-0L317

Report

November 2019

Pages:252

Allied Market Research

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

ONCOLOGY/CANCER DRUGS MARKET OVERVIEW: 2025

The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, a rise in cancer awareness and the availability of cancer drugs are expected to boost market growth.

Cancer has a widespread prevalence worldwide, which has led to a rise in demand for cancer drugs. The key factors that are responsible for the growth of the oncology/cancer drugs market are surge in cancer research, rise in geriatric population worldwide, and an increase in the number of collaborations between pharmaceutical companies. In addition, a rise in healthcare expenditure worldwide is expected to boost the market expansion.

Moreover, high market growth potential in developing nations, a rise in a number of pipeline products, and an upsurge in demand for personalized medicines are expected to create new opportunities for the market players during the forecast period. However, adverse effects associated with the use of cancer drugs and high costs related to cancer drug development are the major factors that impede the growth of the market.

However, the high cost involved in new drug development coupled with the threat of failure & adverse effects associated with cancer drug therapies is expected to restrain the growth of the market. Conversely, the high potential of emerging economies and an increase in the number of pipeline products are expected to provide new opportunities for market players in the future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.Â

Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Key Benefits for Oncology Drugs Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.Â
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

ONCOLOGY DRUGS KEY MARKET SEGMENTS:

By Drug Class TypeÂ

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy

By IndicationÂ

Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers

By Region

North America

U.S.
Canada
Mexico

Europe

Germany
France
UK
Italy
Spain
Rest of Europe

Asia-Pacific

India
China
Japan
Australia
South Korea
Rest of Asia-Pacific

LAMEA

Brazil
South Africa
Saudi Arabia
Rest of LAMEA

ListÂ of Â Key Players Profiled in the Â Report

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Johnson & Johnson (Janssen Global Services, LLC,)
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Sanofi
Amgen Inc.
Bayer AG
Exelixis, Inc

TABLE OF CONTENT

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top winning strategies, 2017

3.3. Top player positioning, 2017

3.4. Porters five forces analysis

3.5. Clinical trials

3.6. Patent analysis (2015-2018)

3.6.1. Patent analysis, world

3.6.2. Patent analysis, by year

3.7. Market dynamics

3.7.1. Drivers

3.7.1.1. Rise in incidence of cancer across the globe

3.7.1.2. Surge in global geriatric population

3.7.1.3. Increase in government expenditures on healthcare

3.7.2. Restraints

3.7.2.1. Adverse effects associated with the use of cancer drugs

3.7.3. Opportunities

3.7.3.1. Untapped emerging economies

3.7.3.2. Increase in number of pipeline drugs

3.7.4. Impact Analyses

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Chemotherapy

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

4.3. Targeted Therapy

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

4.4. Immunotherapy (Biologic Therapy)

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

4.5. Hormonal Therapy

4.5.1. Key market trends, growth factors, and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market analysis, by country

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Lung Cancer

5.2.1. Market size and forecast, by region

5.2.2. Market share analysis, by country

5.3. Stomach Cancer

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

5.4. Colorectal Cancer

5.4.1. Market size and forecast, by region

5.4.2. Market share analysis, by country

5.5. Breast Cancer

5.5.1. Market size and forecast, by region

5.5.2. Market share analysis, by country

5.6. Prostate Cancer

5.6.1. Market size and forecast, by region

5.6.2. Market share analysis, by country

5.7. Liver Cancer

5.7.1. Market size and forecast, by region

5.7.2. Market share analysis, by country

5.8. Esophagus Cancer

5.8.1. Market size and forecast, by region

5.8.2. Market share analysis, by country

5.9. Cervical Cancer

5.9.1. Market size and forecast, by region

5.9.2. Market share analysis, by country

5.10. Kidney Cancer

5.10.1. Market size and forecast, by region

5.10.2. Market share analysis, by country

5.11. Bladder Cancer

5.11.1. Market size and forecast, by region

5.11.2. Market share analysis, by country

5.12. Other Cancers

5.12.1. Market size and forecast, by region

5.12.2. Market share analysis, by country

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type

6.2.2.1.2. U.S. oncology/cancer drugs market, by indication

6.2.2.2. Canada

6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type

6.2.2.2.2. Canada oncology/cancer drugs market, by indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type

6.2.2.3.2. Mexico oncology/cancer drugs market, by indication

6.2.3. Market size and forecast, by drug class type

6.2.4. Market size and forecast, by indication

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type

6.3.2.1.2. Germany oncology/cancer drugs market, by indication

6.3.2.2. France

6.3.2.2.1. France oncology/cancer drugs market, by drug class type

6.3.2.2.2. France oncology/cancer drugs market, by indication

6.3.2.3. UK

6.3.2.3.1. UK oncology/cancer drugs market, by drug class type

6.3.2.3.2. UK oncology/cancer drugs market, by indication

6.3.2.4. Italy

6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type

6.3.2.4.2. Italy oncology/cancer drugs market, by indication

6.3.2.5. Spain

6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type

6.3.2.5.2. Spain oncology/cancer drugs market, by indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type

6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication

6.3.3. Market size and forecast, by drug class type

6.3.4. Market size and forecast, by indication

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type

6.4.2.1.2. Japan oncology/cancer drugs market, by indication

6.4.2.2. China

6.4.2.2.1. China oncology/cancer drugs market, by drug class type

6.4.2.2.2. China oncology/cancer drugs market, by indication

6.4.2.3. Australia

6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type

6.4.2.3.2. Australia oncology/cancer drugs market, by indication

6.4.2.4. India

6.4.2.4.1. India oncology/cancer drugs market, by drug class type

6.4.2.4.2. India oncology/cancer drugs market, by indication

6.4.2.5. South Korea

6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type

6.4.2.5.2. South Korea oncology/cancer drugs market, by indication

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type

6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication

6.4.3. Market size and forecast, by drug class type

6.4.4. Market size and forecast, by indication

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type

6.5.2.1.2. Brazil oncology/cancer drugs market, by indication

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type

6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication

6.5.2.3. South Africa

6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type

6.5.2.3.2. South Africa oncology/cancer drugs market, by indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type

6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication

6.5.3. Market size and forecast, by drug class type

6.5.4. Market size and forecast, by indication

CHAPTER 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

7.1.6. Key strategic moves and developments

7.2. Astellas Pharma Inc.

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product Portfolio

7.2.5. Business performance

7.3. AstraZeneca PLC

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

7.3.6. Key strategic moves and developments

7.4. Bristol-Myers Squibb Company

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product Portfolio

7.4.5. Business performance

7.4.6. Key strategic moves and developments

7.5. Celgene Corporation

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product type Portfolio

7.5.5. Business performance

7.6. F. HOFFMANN-LA ROCHE LTD.

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

7.8. Merck & Co., Inc.

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

7.9. Novartis AG

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

7.10. Pfizer Inc.

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)

TABLE 02. CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 20162023 ($MILLION)

TABLE 03. CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 20172025 ($MILLION)

TABLE 04. CANCER DRUGS FOR IMMUNOTHERAPY, BY REGION, 20172025 ($MILLION)

TABLE 05. CANCER DRUGS FOR HORMONAL THERAPY, BY REGION, 20172025 ($MILLION)

TABLE 06. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)

TABLE 07. ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 20172025 ($MILLION)

TABLE 08. ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 20172025 ($MILLION)

TABLE 09. ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 20172025 ($MILLION)

TABLE 10. ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 20172025 ($MILLION)

TABLE 11. CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 20172025 ($MILLION)

TABLE 12. ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 20172025 ($MILLION)

TABLE 13. ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 20172025 ($MILLION)

TABLE 14. ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 20172025 ($MILLION)

TABLE 15. ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 20172025 ($MILLION)

TABLE 16. ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 20172025 ($MILLION)

TABLE 17. ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 20172025 ($MILLION)

TABLE 18. ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 ($MILLION)

TABLE 19. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)

TABLE 20. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 21. U.S. CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 22. CANADA CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 23. CANADA CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 24. MEXICO CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 25. MEXICO CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 26. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)

TABLE 27. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)

TABLE 28. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)

TABLE 29. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 30. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 31. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 32. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 33. UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 34. UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 35. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 36. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 37. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 38. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 39. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 40. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 41. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)

TABLE 42. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)

TABLE 43. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)

TABLE 44. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 45. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 46. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 47. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 48. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 49. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 50. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 51. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 52. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 53. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 54. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 55. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 56. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)

TABLE 57. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)

TABLE 58. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)

TABLE 59. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 60. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 61. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 62. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 63. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 64. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 65. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025

TABLE 66. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025

TABLE 67. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)

TABLE 68. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)

TABLE 69. ABBVIE: COMPANY SNAPSHOT

TABLE 70. ABBVIE: OPERATING SEGMENTS

TABLE 71. ABBOTT: PRODUCT PORTFOLIO

TABLE 72. ASTELLAS: COMPANY SNAPSHOT

TABLE 73. ASTELLAS: PRODUCTS AND SERVICES

TABLE 74. ASTELLAS: PRODUCT PORTFOLIO

TABLE 75. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 76. ASTRAZENECA: OPERATING SEGMENTS

TABLE 77. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 78. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 79. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 80. CELGENE: COMPANY SNAPSHOT

TABLE 81. CELGENE: OPERATING SEGMENTS

TABLE 82. CELGENE : PRODUCT TYPE PORTFOLIO

TABLE 83. ROCHE: COMPANY SNAPSHOT

TABLE 84. ROCHE: OPERATING SEGMENTS

TABLE 85. ROCHE: PRODUCT TYPE PORTFOLIO

TABLE 86. J&J: COMPANY SNAPSHOT

TABLE 87. J&J: OPERATING SEGMENTS

TABLE 88. J&J: PRODUCT TYPE PORTFOLIO

TABLE 89. MERCK: COMPANY SNAPSHOT

TABLE 90. MERCK: OPERATING SEGMENTS

TABLE 91. MERCK: PRODUCT PORTFOLIO

TABLE 92. NOVARTIS: COMPANY SNAPSHOT

TABLE 93. NOVARTIS: OPERATING SEGMENTS

TABLE 94. NOVARTIS: PRODUCT PORTFOLIO

TABLE 95. PFIZER: COMPANY SNAPSHOT

TABLE 96. PFIZER: OPERATING SEGMENTS

TABLE 97. PFIZER: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. TOP WINNING STRATEGIES, 2015-2018

FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2015-2018

FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2015-2018

FIGURE 06. TOP PLAYER POSITIONING, 2017

FIGURE 07. MODERATE BARGANING POWER OF BUYERS

FIGURE 08. HIGH BARGANING POWER OF SUPPLIERS

FIGURE 09. MODERATE THREAT OF SUBSTITUTION

FIGURE 10. MODERATE THREAT OF NEW ENTRANTS

FIGURE 11. HIGH COMPETITIVE RIVALRY

FIGURE 12. PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018

FIGURE 13. PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018

FIGURE 14. WORLD POPULATION AGED 65 AND OVER (%)

FIGURE 15. IMPACT ANALYSES, ONCOLOGY/CANCER DRUGS MARKET

FIGURE 16. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2017 & 2025

FIGURE 17. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2017 & 2025

FIGURE 18. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR IMMUNOTHERAPY, BY COUNTRY, 2017 & 2025

FIGURE 19. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR HORMONAL THERAPY, BY COUNTRY, 2017 & 2025

FIGURE 20. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2017 & 2025

FIGURE 21. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2017 & 2025

FIGURE 22. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017 & 2025

FIGURE 23. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2017 & 2025

FIGURE 24. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017 & 2025

FIGURE 25. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2017 & 2025

FIGURE 26. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2017 & 2025

FIGURE 27. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2017 & 2025

FIGURE 28. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2017 & 2025

FIGURE 29. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2017 & 2025

FIGURE 30. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017 & 2025

FIGURE 31. EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017

FIGURE 32. ABBVIE: NET SALES, 20152017 ($MILLION)

FIGURE 33. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 34. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 35. ASTELLAS: SALES, 20152017 ($MILLION)

FIGURE 36. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)

FIGURE 37. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 38. ASTRAZENECA: REVENUE, 20152017 ($MILLION)

FIGURE 39. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 40. REVENUE, 20152017 ($MILLION)

FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 42. CELGENE: REVENUE, 20152017 ($MILLION)

FIGURE 43. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 44. CELGENE: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 45. ROCHE: NET SALES, 20152017 ($MILLION)

FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 48. J&J: REVENUE, 20152017 ($MILLION)

FIGURE 49. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 50. J&J: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 51. MERCK: NET SALES, 20152017 ($MILLION)

FIGURE 52. MERCK: NET SALES BY SEGMENT, 2017 (%)

FIGURE 53. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)

FIGURE 54. NET SALES, 20152017 ($MILLION)

FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 56. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 57. PFIZER: REVENUE, 20152017 ($MILLION)

FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 59. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$5370

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$6450

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$8995

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Published Date: November 2019

Report Code: ALLI-Auto-0L317

ONCOLOGY/CANCER DRUGS MARKET OVERVIEW: 2025

Key Benefits for Oncology Drugs Market:

ONCOLOGY DRUGS KEY MARKET SEGMENTS:

By Drug Class TypeÂ

By IndicationÂ

By Region

ListÂ of Â Key Players Profiled in the Â Report

TABLE OF CONTENT

LIST OF TABLES

RELATED REPORTS